Top Headlines

EU revives GMP for excipients

The EFCG has welcomed the addition of excipient GMP requirements to the draft amendments of the EU falsified medicines directive but warned that deeper analysis is needed to establish which products warrant further regulation.

Actavis to boost tablet capacity; and looking at Ratiopharm

Icelandic generics firm Actavis says expansion of its tablet plant will boost production capacity 50 per cent and create 50 new jobs.

ISCO stem cell production site passes building inspection

ISCO’s stem cell manufacturing facility has passed final building inspection, enabling it to implement the processes and cGMP standards needed to produce clinical-grade products.

Pharmadule targets China with Morimatsu accord

Pharmadule has teamed up with Morimatsu to capture a share of Chinese pharma and biotech manufacturing markets’ “huge potential.”

Pfizer, Roche and GSK report 2009 results

In a busy week of Big Phama results Pfizer reports sales boost from Wyeth, Roche says Genentech hit profits and GSK unveils surge in Relenza sales and plans to expand R&D restructuring.

News in brief

Today's headlines across the Pharmaceutical industry

Phase Forward says ICRS a must for data management market from Outsourcing-Pharma.com

Integrated solutions are the future of trial data management according to Phase Forward as growth of the electronic data capture (EDC) market begins to slow.

BioClinica and Cephalon ink data management deal from Outsourcing-Pharma.com

BioClinica is providing Cephalon with end-to-end clinical data management services and hiring some of the biotech’s staff under a three-year, multi-million dollar deal.

News in brief

Gorbec opening analytical laboratory in China from Outsourcing-Pharma.com

Gorbec Pharmaceutical Services is opening a GMP compliant analytical laboratory in Yantai, China to improve the service it offers to US-based clients and expand its presence in Asia.

MENA emerging as trial destination says ClinTec CEO from Outsourcing-Pharma.com

Improving healthcare infrastructure across the region and a large treatment-naïve patient population makes the Middle East and North Africa (MENA) an increasingly attractive destination for drug trials says ClinTec CEO Rabinder Buttar.

On your radar